Chris Yamamoto serves as Senior Vice President of Corporate Development & Strategy and is responsible for group functions at Bioventus, including strategy, business development, integration, market access, reimbursement, pricing and market insights. Chris has 20 years of mergers & acquisitions, strategy and investment experience having completed transactions amounting to over $50 billion in value across the medical technology, life sciences and industrial sectors.

Prior to joining Bioventus, Chris was Vice President and Managing Director of Corporate Development at Becton Dickinson and Company. During his tenure at Becton Dickinson, Chris played an instrumental role in transforming the company through two large-scale acquisitions (C.R. Bard and CareFusion), executing nearly 30 tuck-in acquisitions and equity investments and divesting a number of non-core businesses. Prior to Becton Dickinson, Chris was a Vice President at The Blackstone Group. Chris also worked at Fox Paine, Thoma Cressey, UBS Investment Bank and other institutions.

Chris received a Bachelor of Arts in Economics cum laude from Williams College.